Healthcare Business Update: Astex Sees EU Okay, Pozen Prevails In Court Ruling

| + More Articles
  • Like on Facebook
  • Share on Google+
  • Share on LinkedIn

Astex Pharmaceuticals (ASTX) announces that its drug Dacogen which treats a type of leukemia, has been approved by the European Commission, calling it “the world’s first medicine approved and labeled specifically for elderly acute myeloid leukemia.” The company receives royalties from its licensee Eisai and anticipates $17.5 million in future payments should milestones continue worldwide. Eisai holds marketing and development rights in North America.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Pozen’s (NASDAQ:POZN) previous lower court decision against Par Pharmaceutical Companies (NYSE:PRX), Dr. Reddy’s Laboratories Limited (NYSE:RDY), and Alphapharm has been upheld by a United States appeals court. The prior ruling found Pozen’s patent valid, and blocked Par and Dr. Reddy’s from selling a generic version of its migraine drug Treximet until 2025.

Don’t Miss: How Bad is the Student Debt Bubble?


More Articles About:

To contact the reporter on this story: staff.writers@wallstcheatsheet.com To contact the editor responsible for this story: editors@wallstcheatsheet.com

Yahoo Finance, Harvard Business Review, Market Watch, The Wall St. Journal, Financial Times, CNN Money, Fox Business